title: What's new in the treatment of portopulmonary hypertension?
abstract: Portopulmonary hypertension (POPH) is a complication of portal hypertension characterized by pulmonary vasoconstriction and vascular remodeling that can lead to right heart failure and death. Differentiation of POPH from other causes of pulmonary hypertension, such as volume overload or a hyperdynamic high flow state, is critical because a diagnosis of POPH has significant implications for liver transplant risk stratification, Model for End Stage Liver Disease exception points, and the use of pulmonary arterial hypertension-(PAH) specific therapy. Currently, there are 12 approved medications for the treatment of PAH in the US, and three of these were approved in 2013. This review will discuss the diagnosis, evaluation and management of POPH and the role of recently approved PAH therapies in the treatment of POPH.
authors.affiliation: Massachusetts General Hospital, 55 Fruit St Boston MA 02114, USA.
authors.forename: Hilary M
authors.initials: HM
authors.lastname: DuBrock
authors.forename: Richard N
authors.initials: RN
authors.lastname: Channick
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Krowka
mesh_terms: D006333:Heart Failure / Q000209:etiology; D006801:Humans; D006975:Hypertension, Portal / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D016031:Liver Transplantation; D011379:Prognosis; D011651:Pulmonary Artery; D066253:Vascular Remodeling; D014661:Vasoconstriction
keywords: macitentan; portopulmonary hypertension; pulmonary arterial hypertension; riociguat; treatment; treprostinil